Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
29.36
+0.05 (0.17%)
Jul 28, 2026, 4:00 PM EDT - Market closed

Stoke Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
32.08184.4236.568.7812.41-
Revenue Growth
-83.20%404.50%316.34%-29.22%--
Gross Profit
32.08184.4236.568.7812.41-
Operating Income
-185.25-20.59-101.37-114.77-104.36-86.07
Net Income
-169.77-6.89-88.98-104.7-101.07-85.81
Earnings Per Share
-2.84-0.12-1.65-2.38-2.60-2.34
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash (Debt)
343.55285.16216.97201.39229.6219.81
Net Cash Growth
-3.88%31.43%7.74%-12.28%4.45%-23.49%
Cash & Investments
343.55285.16216.97201.39229.6219.81
Net Cash Per Share
5.684.824.024.585.905.98

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-146.8245.59-86.85-81.07-31.87-66.91
Capital Expenditures
-0.87-0.67-0.2-1.62-3.96-1.2
Free Cash Flow
-147.744.92-87.05-82.68-35.83-68.11
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%-
Operating Margin
-577.46%-11.16%-277.31%-1307.21%-841.24%-
Pretax Margin
-533.18%-3.73%-243.42%-1192.47%-814.73%-
Profit Margin
-529.20%-3.73%-243.42%-1192.47%-814.73%-
FCF Margin
-460.40%24.35%-238.15%-941.72%-288.82%-

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
P/FCF Ratio
-41.64----
PS Ratio
56.3810.1416.3027.5129.35-